Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants
Conditions
Interventions
Maribavir
Placebo
Locations
13
United States
City of Hope Medical Center
Duarte, California, United States
UCLA Medical Center
Los Angeles, California, United States
Loyola University
Maywood, Illinois, United States
Tufts-New England Medical Center
Boston, Massachusetts, United States
Wayne State Medical Center
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Start Date
October 28, 2004
Primary Completion Date
April 5, 2006
Completion Date
April 5, 2006
Last Updated
May 13, 2021
NCT07294547
NCT06926894
NCT07013370
NCT05626530
NCT02007356
NCT06027879
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions